MORGAN STANLEY PLC/CALL/AMGEN/460/0.1/21.03.25 | Market Closed - Börse Stuttgart 15:00:55 2024-05-17 EDT | ||
| 0.34 EUR | -8.11% |
|
| Current month | +91.01% | ||
| 1 month | +65.85% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 0.34 | -8.11% |
| 24-05-16 | 0.37 | -5.13% |
| 24-05-15 | 0.39 | +11.43% |
| 24-05-14 | 0.35 | +6.06% |
| 24-05-13 | 0.33 | 0.00% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 03:00 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | ME6QP7 |
| ISIN | DE000ME6QP74 |
| Date issued | 2024-01-10 |
| Strike | 460 $ |
| Maturity | 2025-03-21 (308 Days) |
| Parity | 10 : 1 |
| Emission price | 0.32 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.47 € |
|---|---|
| Lowest since issue | 0.13 € |
| Spread | 0.03 € |
| Spread % | 8.11% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
312.5
USD
Average target price
314.1
USD
Spread / Average Target
+0.51%
- Stock Market
- Warrants
- Warrant
